Zhaohui Zheng

Sun Yat-sen University — China

Medicine · Health Sciences

25h-index12.7kcitations61works2.42yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

CAR-T cell therapy research(42), Chronic Lymphocytic Leukemia Research(16), Immunotherapy and Immune Responses(13), Lymphoma Diagnosis and Treatment(12), Acute Lymphoblastic Leukemia research(8)

Publications61 total

Epigenetic reprogramming via EZH1/2 inhibition enhances T cell-mediated immunotherapies against multiple myeloma
Blood·2025Open Access
Genome‐based polyphasic taxonomy of desert‐derived <i>Kineococcus</i> reveals nine novel species with plant growth‐promoting traits
Journal of Systematics and Evolution·2025· 1 citedOpen Access
Effects of deep brain stimulation of the nucleus accumbens and anterior limb of the internal capsule on heroin addiction: Over five years of long-term follow-up in a prospective open-label pilot study
Translational Psychiatry·2025· 2 citedOpen Access
Evaluation of the therapeutic effect of adaptive deep brain stimulation on motor symptoms and sleep disturbances in Parkinson’s disease and construction of a response prediction model
Frontiers in Neurology·2025Open Access
The Prospective Registry Of MyositIS (PROMIS): II. Temporal shifts in causes of death among patients with idiopathic inflammatory myopathies
Journal of the American Academy of Dermatology·2025· 3 citedOpen Access
Deep Brain Stimulation in Parkinson's Disease Patients Over 75 Years of Age: A Single‐Institution Retrospective Analysis
CNS Neuroscience & Therapeutics·2025· 1 citedOpen Access
Data-Driven Clustering Analysis Characterizing Systemic Sclerosis and the Association with Clinical Implications and Survival
SSRN Electronic Journal·2025Open Access
The immunomodulatory of interleukin-33 in rheumatoid arthritis: A systematic review
Clinical Immunology·2024· 12 cited
Data from Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia
2023Open Access
Data from Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia
2023Open Access
Development and Validation of the Five-Dimension Comprehensive Assessment Scale (5dcas) for Assessing Physical Function and Health in Axial Spondyloarthritis: A Multicenter, Rasch Analysis-Based Cross-Sectional Survey
SSRN Electronic Journal·2023Open Access
Combination Immunotherapy of Glioblastoma with Dendritic Cell Cancer Vaccines, Anti-PD-1 and Poly I:C: A Case Report
2022Open Access
Role of the Cortico-Subthalamic Hyperdirect Pathway in Deep Brain Stimulation for the Treatment of Parkinson Disease: A Diffusion Tensor Imaging Study
World Neurosurgery·2018· 32 cited
A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma
Science Translational Medicine·2017· 1.7k citedOpen Access
Abstract LB-083: Phase I study of T cells redirected to EGFRvIII with a chimeric antigen receptor in patients with EGFRvIII+ glioblastoma
Cancer Research·2016· 4 cited
Durable Remissions with Control of Cytokine Release Syndrome (CRS) Using T Cells Expressing CD19 Targeted Chimeric Antigen Receptor (CAR) CTL019 to Treat Relapsed/Refractory (R/R) Acute Lymphoid Leukemia (ALL)
Cytotherapy·2016
Pilot study of T cells redirected to EGFRvIII with a chimeric antigen receptor in patients with EGFRvIII+ glioblastoma.
Journal of Clinical Oncology·2016· 31 cited
Recovery of humoral immunity in patients with durable complete responses following chimeric antigen receptor modified t cells directed against CD19 (CTL019).
Journal of Clinical Oncology·2016· 10 cited
Sustained remissions with CD19-specific chimeric antigen receptor (CAR)-modified T cells in children with relapsed/refractory ALL.
Journal of Clinical Oncology·2016· 148 cited
Efficacy of humanized CD19-targeted chimeric antigen receptor (CAR)-modified T cells in children with relapsed ALL.
Journal of Clinical Oncology·2016· 24 cited
page 1 of 4Next →

Frequent Co-authors

Bruce L. Levine(42), Carl H. June(39), Simon F. Lacey(19), J. Joseph Melenhorst(17), Julio Cotte(16), Elizabeth Veloso(14), David L. Porter(12), Edward A. Stadtmauer(12), Anne Chew(11), Stephen J. Schuster(11), Stephan A. Grupp(10), Dan T. Vogl(10), Aaron P. Rapoport(9), Nicole A. Aqui(9), Michael Kalos(9), Katherine T. Marcucci(8), Ashraf Badros(8), Görgün Akpek(8), Jakub Svoboda(8), Elise A. Chong(8)